2nd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Period 2nd Quarter 2010 Filed Jul 20, 2010 Signed by Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel

Official filing
Firm
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Client
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Income
—
Expenses
$4,650,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements Korea Free Trade Agreement: intellectual property, market access and public health Trans-Pacific Strategic Economic Partnership Agreement (TPP): intellectual property issues Special 301 submission Preference Program Reform International market access and intellectual property issues Trade enforcement issues

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
LEA FISHER —
TOM MOORE —
MATTHEW L SULKALA —

Contacted: White House Office; Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Office of Management & Budget (OMB); Congressional Budget Office (CBO); SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Bills named: H.R. 3012 (111th)

Health Issues HCR

H.R. 444, 340B Program Improvement and Integrity Act: 340B drug pricing program issues H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B drug pricing program issues, drug labeling, access to clinical trials, and other health reform implementation issues H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: 340B drug pricing program and average manufacturer price (AMP) issues H.R. 4489, Federal Employees Health Benefits Plan (FEHBP) Prescription Drug Integrity, Transparency, and Cost Savings Act: transparency of drug pricing H.R. 4872, Health Care and Education Reconciliation Act of 2010: 340B drug pricing program issues H.R. 4899, Supplemental Appropriations Act, 2010: average manufacturer price (AMP) issues S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1679, Affordable Health Choices Act: 340B program issues, importation, and other health reform implementation issues User fee issues

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER —
JENNIFER MIRANDA BRYANT —
RANDY BURKHOLDER —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM —
ROBERT FILIPPONE —
LEA FISHER —
GREGORY GIERER —
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
DAVID KORN —
HALLIE AMANDA MARANCHICK —
TOM MOORE —
BRIAN NAGLE —
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON —
BILLY TAUZIN —
STEVE TILTON —
MICHAEL PAUL WOODY —

Contacted: SENATE; U.S. Trade Representative (USTR); White House Office; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Food & Drug Administration (FDA); Office of Management & Budget (OMB)

Bills named: H.R. 444 (111th), H.R. 1298 (111th), S. 1232 (111th), H.R. 4899 (111th), H.R. 4872 (111th), H.R. 4489 (111th), S. 1679 (111th), H.R. 4213 (111th), H.R. 3590 (111th), H.R. 2824 (111th), S. 1213 (111th), S. 525 (111th), H.R. 2502 (111th)

Copyright/Patent/Trademark CPT

H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws International intellectual property issues

LobbyistCovered position, as disclosed
DANIEL DURHAM —
ROBERT FILIPPONE —
LEA FISHER —
JAMES BRYANT HALL —
DAVID KORN —
HALLIE AMANDA MARANCHICK —
TOM MOORE —
BRIAN NAGLE —
ANNE PRITCHETT —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
BILLY TAUZIN —
STEVE TILTON —

Contacted: Food & Drug Administration (FDA); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); White House Office; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); State, Dept of (DOS); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR)

Bills named: S. 369 (111th), H.R. 4213 (111th), H.R. 573 (111th), S. 515 (111th), S. 501 (111th), H.R. 4899 (111th), H.R. 1260 (111th), H.R. 1706 (111th), H.R. 5322 (111th), S. 610 (111th)

Medicare/Medicaid MMM

H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, Part D coverage gap discounts, Part D issues generally, Medicare payment issues including the Independent Payment Advisory Board (IPAB), and Medicaid issues H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: non-interference provisions H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: Medicaid rebate issues H.R. 4872, Health Care and Education Reconciliation Act of 2010: Part D coverage gap discounts, Part D issues generally, Medicaid rebate issues, health reform fee, and other health reform implementation issues generally H.R. 4899, Supplemental Appropriations Act, 2010: Medicaid rebate issues

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER —
RANDY BURKHOLDER —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM —
ROBERT FILIPPONE —
LEA FISHER —
GREGORY GIERER —
VALERIE HARDIN JEWETT —
ANN KAPLAN —
HALLIE AMANDA MARANCHICK —
TOM MOORE —
BRIAN NAGLE —
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON —
BILLY TAUZIN —
STEVE TILTON —
MICHAEL PAUL WOODY —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); White House Office; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Patent & Trademark Office (PTO); SENATE; Agency for Healthcare Research & Quality (AHRQ); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4213 (111th), H.R. 4872 (111th), H.R. 3590 (111th), H.R. 4899 (111th), H.R. 4752 (111th)

Environment/Superfund ENV

H.R. 5320, The Assistance, Quality, and Affordability Act of 2010: provisions relating to a study on the presence of pharmaceuticals and personal care products in the water supply

LobbyistCovered position, as disclosed
LEA FISHER —
TOM MOORE —
BRIAN NAGLE —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Agency for Healthcare Research & Quality (AHRQ); White House Office; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Food & Drug Administration (FDA)

Bills named: H.R. 5320 (111th)

Budget/Appropriations BUD

H.R. 4899, Supplemental Appropriations Act, 2010: Provisions relating to the Strategic National Stockpile and disclosure of certain information by DOD contractors FY 2011 Agriculture, FDA, and Rural Development Appropriations Bill: FDA funding

LobbyistCovered position, as disclosed
DAVID BOYER —
RANDY BURKHOLDER —
ANDREA JEAN DOUGLAS —
ROBERT FILIPPONE —
LEA FISHER —
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
TOM MOORE —
BRIAN NAGLE —
LORI REILLY —
MATTHEW L SULKALA —
BILLY TAUZIN —
STEVE TILTON —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); White House Office; Commerce, Dept of (DOC); Congressional Budget Office (CBO); Agency for Healthcare Research & Quality (AHRQ); SENATE

Bills named: H.R. 4899 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.